AUTOANTIBODIES TO ISLET AMYLOID POLYPEPTIDE IN DIABETES

被引：17

作者：

CLARK, A

YON, SM

DEKONING, EJP

HOLMAN, RR

机构：

[1] Diabetes Research Laboratories, Radcliffe Infirmary, Oxford

来源：

DIABETIC MEDICINE | 1991年 / 8卷 / 07期

关键词：

ELISA; ISLET AMYLOID POLYPEPTIDE; AUTOANTIBODIES; DIABETES;

D O I：

10.1111/j.1464-5491.1991.tb01675.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Islet amyloid polypeptide (IAPP) is the constituent peptide of amyloid in pancreatic islets of Type 2 diabetic patients and in insulinomas. Amyloid formation in Type 2 diabetes is associated with islet cell destruction which may promote formation of autoantibodies to IAPP. An ELISA method has been developed to detect IAPP autoantibodies and used to assay serum from 80 non-diabetic subjects, 49 Type 1 and 228 Type 2 diabetic patients, and 10 patients with insulinomas. Microtitre plates coated with IAPP1-37 were used to detect antibody binding followed by an alkaline phosphatase conjugated anti-human IgG. ELISA binding decreased with sample dilution and with pre-incubation of the samples with IAPP. The optical density of the substrate reaction was compared with results from a standard serum from a non-diabetic subject (OD ratio). Elevated OD ratios were detected in some subjects from each patient group but the Type 2 diabetic group had significantly higher titres than the non-diabetic subjects (p < 0.001). The OD ratio was elevated (> mean+2SD non-diabetic group) in 15 % of Type 2 and 18 % of Type 1 diabetic patients and in 20 % with insulinomas. IAPP antibody levels did not correlate with age or gender of subjects, or duration of diabetes. IAPP autoantibodies could be an additional marker for B-cell damage in diabetes.

引用

页码：668 / 673

页数：6

共 23 条

[1] Bottazzo GF, Florin-Christensen A., Doniach D., Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies, Lancet, 2, pp. 1279-1283, (1974)
[2] Dobersen MJ, Scharff JE, Ginsberg-Fellner F., Notkins AL, Cytotoxic autoantibodies to beta cells in the serum of patients with insulin dependent diabetes mellitus, N Engl J Med, 303, pp. 1493-1498, (1980)
[3] Lernmark A., Islet cell antibodies, Diabetic Med, 4, pp. 285-292, (1987)
[4] Palmer JP, Asplin CM, Clemons P., Lyen K., Tatpati O., Raghu PK, Et al., Insulin antibodies in insulin‐dependent diabetics before insulin treatment, Science, 222, pp. 1337-1339, (1983)
[5] Christie M., Landin-Olsson M., Sundkvist G., Dahlquist G., Lernmark A., Antibodies to a M<sub>r</sub>‐64000 islet cell protein in Swedish children with newly diagnosed Type 1 (non‐insulin dependent) diabetes, Diabetologia, 31, pp. 597-602, (1988)
[6] Baekkeskov S., Aanstoot H-J, Christgau S., Reetz A., Solimena M., Cascalho M., Et al., Identification of the 64 K autoantigen in insulin‐dependent diabetes as the GABA‐synthesizing enzyme glutamic acid decarboxylase, Nature, 347, pp. 151-156, (1990)
[7] Bonifacio E., Bingley PJ, Shattock M., Dean BM, Dunger D., Gale EAM, Et al., Quantification of islet‐cell antibodies and prediction of insulin dependent diabetes, Lancet, 335, pp. 147-149, (1990)
[8] Clark A., Islet amyloid and Type 2 diabetes, Diabetic Med, 6, pp. 561-567, (1989)
[9] Clark A., Saad MF, Nezzer T., Uren C., Knowler WC, Bennett PH, Et al., Islet amyloid polypeptide in diabetic and non‐diabetic Pima Indians, Diabetologia, 33, pp. 285-289, (1990)
[10] Westermark P., Wernstedt C., Wilander E., Hayden D., O'Brien T., Johnson K., Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide‐like protein also present in normal islet cells, Proc Natl Acad Sci, 84, pp. 3881-3885, (1987)

← 1 2 3 →